1. "2021"
Formats
  1. Journal Article (2507)
  2. Meeting Abstract (1731)
  3. Review (604)
  4. Editorial (358)
  5. Book Section (123)
  6. Correspondence (107)
  7. Guidelines (103)
  8. Research Letter (91)
  9. Miscellaneous (52)
  10. Conference Paper (34)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2534)
  2. Solid Tumor Oncology Division (1517)
  3. Sloan Kettering Institute Postdocs (1176)
  4. GSK Faculty (1088)
  5. Surgery (954)
  6. Survivorship Research (922)

More Groups

People
  1. Alexander Drilon (76)
  2. Miguel-Angel Perales (68)
  3. Sergio Giralt (66)
  4. Robert Motzer (65)
  5. Marc Ladanyi (62)
  6. Monica Morrow (57)

More People

Years
  1. 2021 (5712)
Publications
  1. Journal of Clinical Oncology (471)
  2. Blood (252)
  3. Annals of Oncology (148)
  4. Cancer Research (145)
  5. International Journal of Radiation Oncology, Biology, Physics (145)
  6. Journal of Thoracic Oncology (101)

More Publications

Publishers
  1. Elsevier Inc. (723)
  2. American Society of Clinical Oncology (522)
  3. Springer (381)
  4. Oxford University Press (360)
  5. Nature Publishing Group (344)
  6. American Association for Cancer Research (297)

More Publishers

Results (5712)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mechanisms of acquired resistance to KRAS G12C inhibition in cancer
    Meeting Abstract

    Awad, M.; Liu, S.; Arbour, K.; Zhu, V.; Johnson, M.; Heist, R.; Patil, T.; Riely, G.; Jacobson, J.; Dilly, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC
    Meeting Abstract

    Ricciuti, B.; Arbour, K. C.; Mahadevan, N. R.; Alessi, J. V.; Lindsay, J.; Umeton, R.; Sinha, R.; Hoojghan, A.; Vokes, N.; Recondo, G.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Tebentafusp induces transient systemic inflammation and modifies the micro-environment to sensitize uveal melanoma tumors to cytotoxic CD8 cells
    Meeting Abstract

    Butler, M. O.; Stanhope, S.; Naidoo, R.; Leach, E.; Kaur, S.; Collins, L.; Abdullah, S.; Ranade, K.; Shoushtari, A. N.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Cholesterol metabolism gene expression and prostate cancer-specific outcomes in radiotherapy-treated patients
    Meeting Abstract

    Winter, S. J.; Halliday, S.; Stopsack, K. H.; Osman, S. O.; Hounsell, A. R.; Prue, G.; Jain, S.; Allott, E. H.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Molecular characteristics of repotrectinib that enable potent inhibition of TRK fusion proteins and broad mutant selectivity
    Meeting Abstract

    Drilon, A.; Zhai, D.; Rogers, E.; Deng, W.; Chen, X.; Sprengeler, P.; Reich, S. H.; Murray, B. W.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Decoding the intimate dialogues between stem cells and immune cell for cancer immunotherapy
    Meeting Abstract

    Truong, C.; Guo, W.; Rudensky, A.; Fuchs, E.; Miao, Y. P.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Identification and characterization of the PIK3R1-mutant subtype in PI3K-addicted prostate cancer
    Meeting Abstract

    Chakraborty, G.; Nandakumar, S.; Hirani, R.; Rajanala, S. H.; Nguyen, B.; Ghale, R.; Mazzu, Y. Z.; Jehane, L. E.; Lee, G. S. M.; Mucci, L. A.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • PRMT5 inhibition regulates alternative splicing and DNA damage repair pathways in SF3B1 R625G expressing uveal melanoma cells
    Meeting Abstract

    Ito, K.; Thodima, V.; Carter, J.; Bhagwat, N.; Sivakumar, M.; Grego, A.; Rager, J.; Terai, M.; Sato, T.; Abdel-Wahab, O.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Epigenetic mechanisms of endocrine therapy response in breast cancer
    Meeting Abstract

    Toska, E.; Xu, G.; Arruabarrena-Aristorena, A.; Scaltriti, M.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • ENVASARC: A pivotal trial of envafolimab, and envafolimab in combination with ipilimumab, in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy
    Meeting Abstract

    D'Angelo, S.; Robinson, S.; Lam, J.; Adams, B.; Freddo, J.; Theuer, C. P.; Maki, R.
    Cancer Research (2021)

    Fulltext@MSK | Save